Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC
In the first-line treatment of patients with EGFR-mutated locally advanced or metastatic non–small-cell lung cancer (NSCLC), the novel third-generation EGFR tyrosine kinase inhibitor rezivertinib yields superior overall efficacy and progression-free survival (PFS) when compared with gefitinib, with no new safety signals, according to the phase III REZOR trial.
